GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Change In Receivables

BGI Genomics Co (SZSE:300676) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Change In Receivables?

BGI Genomics Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means BGI Genomics Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

BGI Genomics Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥736 Mil. It means BGI Genomics Co's Accounts Receivable declined by ¥736 Mil from Dec. 2022 to Dec. 2023 .

BGI Genomics Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥1,564 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. BGI Genomics Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 173.75.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BGI Genomics Co's liquidation value for the three months ended in Mar. 2024 was ¥3,317 Mil.


BGI Genomics Co Change In Receivables Historical Data

The historical data trend for BGI Genomics Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Change In Receivables Chart

BGI Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -421.61 -471.96 254.15 -1,085.95 736.49

BGI Genomics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BGI Genomics Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BGI Genomics Co  (SZSE:300676) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BGI Genomics Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1563.706/821.25*91
=173.75

2. In Ben Graham's calculation of liquidation value, BGI Genomics Co's accounts receivable are only considered to be worth 75% of book value:

BGI Genomics Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5260.818-3413.525+0.75 * 1563.706+0.5 * 593.453
=3,317

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BGI Genomics Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of BGI Genomics Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BGI Genomics Co (SZSE:300676) Business Description

Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Xu Qian Secretary Dong
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines